Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Borchmann P, et al. Among authors: kaul h. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. Epub 2024 Jul 3. Lancet. 2024. PMID: 38971175 Free article. Clinical Trial.
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Kreissl S, Voltin CA, Kaul H, Bühnen I, Mettler J, Pabst T, Eichenauer DA, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Kobe C. Kreissl S, et al. Among authors: kaul h. Br J Haematol. 2022 Apr;197(1):e5-e8. doi: 10.1111/bjh.17997. Epub 2021 Dec 20. Br J Haematol. 2022. PMID: 34929056 No abstract available.
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
Jacob AS, Kaul H, Fuchs M, Gillessen S, Kreissl S, Pluetschow A, Momotow J, Schaub V, Huettmann A, Haenel M, Zimmermann A, Dierlamm J, Meissner J, Mathas S, Martin S, Engert A, Hallek M, Borchmann P, Lehmann C. Jacob AS, et al. Among authors: kaul h. Infection. 2022 Aug;50(4):925-932. doi: 10.1007/s15010-022-01765-3. Epub 2022 Feb 19. Infection. 2022. PMID: 35182355 Free PMC article.
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Bröckelmann PJ, et al. Among authors: kaul h. J Clin Oncol. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. J Clin Oncol. 2023. PMID: 36508302 Clinical Trial.
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
Eichenauer DA, Bühnen I, Baues C, Kobe C, Kaul H, Greil R, Moccia A, Zijlstra JM, Hertenstein B, Topp MS, Just M, von Tresckow B, Eich HT, Fuchs M, Dietlein M, Hartmann S, Engert A, Borchmann P. Eichenauer DA, et al. Among authors: kaul h. Blood. 2023 Aug 10;142(6):553-560. doi: 10.1182/blood.2023019939. Blood. 2023. PMID: 37257195 Free article.
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
van Heek L, Weindler J, Gorniak C, Kaul H, Müller H, Mettler J, Baues C, Fuchs M, Borchmann P, Ferdinandus J, Dietlein M, Voltin CA, Kobe C, Roth KS. van Heek L, et al. Among authors: kaul h. Eur J Haematol. 2023 Dec;111(6):881-887. doi: 10.1111/ejh.14093. Epub 2023 Aug 29. Eur J Haematol. 2023. PMID: 37644732
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA. Fuchs M, et al. Among authors: kaul h. Leukemia. 2024 Jan;38(1):160-167. doi: 10.1038/s41375-023-02064-y. Epub 2023 Oct 16. Leukemia. 2024. PMID: 37845285 Free PMC article. Clinical Trial.
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.
Rosenbrock J, Kaul H, Oertel M, Celik E, Linde P, Fan J, Eichenauer DA, Bröckelmann PJ, von Tresckow B, Kobe C, Dietlein M, Fuchs M, Borchmann P, Eich HT, Baues C. Rosenbrock J, et al. Among authors: kaul h. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1344-1352. doi: 10.1016/j.ijrobp.2024.04.015. Epub 2024 Apr 15. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631539 Free article. Clinical Trial.
Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma.
Müller-Meinhard B, Seifert N, Grund J, Reinke S, Yalcin F, Kaul H, Borchmann S, von Tresckow B, Borchmann P, Plütschow A, Richter J, Engert A, Altenbuchinger M, Bröckelmann PJ, Klapper W. Müller-Meinhard B, et al. Among authors: kaul h. Hemasphere. 2024 Jun 3;8(6):e84. doi: 10.1002/hem3.84. eCollection 2024 Jun. Hemasphere. 2024. PMID: 38836098 Free PMC article.
170 results